12.22
+1.41%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Certara
From its filings with the US Securities and Exchange Commission
Certara is based in Radnor, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CERT. The SEC classifies its business as prepackaged software. In the fiscal year to 31 December 2025, it reported revenue of $418.8m and a net loss of $1.6m. At that date it held total assets of $1.56bn and shareholders' equity of $1.06bn.
We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development (“MIDD”) in the global biopharmaceutical and biotech industry. MIDD is an approach that utilizes biological and statistical models derived from preclinical, clinical, and evidence data to inform decision-making in drug research and development, and commercialization. Biosimulation is a critical component of MIDD that uses computer-aided mathematical simulation of biological processes and systems to understand the action of a drug in a human body or a population of humans.
Biosimulation and hereby MIDD can increase the probability of success in bringing a new drug to market, accelerate its development and decrease the costs of drug development. There are many examples of currently approved drugs where models were successfully used in discovery, preclinical, first-in-human dose predictions, clinical trial simulations and protocol design, and for drug interaction label claims. Biosimulation is also used to support drug development beyond the approval stage; examples include determining formulation or manufacturing changes and label extensions. In addition, MIDD strategies are increasingly utilized to help predict commercial success, a critical part of the drug research and development process as new products must be both approved by regulators and adopted by the market.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 11 Dec 2020
- Employees
- 1,515
- Website
- certara.com ↗
- Head office
- 4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR, PA, 19087
- Incorporated in
- DE
- Classification
- Services-Prepackaged Software
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. James CashmanIndependent Chairman of the Board$319,479
- Mr. Leif PedersenPresident, Chief Commercial Officer$2.1m
- Dr. William FeeheryChief Executive Officer, Director, since 2019$7.2m
- Mr. John GallagherChief Financial Officer, Senior Vice President$2.9m
- Dr. Robert AspburyPresident - Certara Predictive Technologies$2.0m
- Mr. Adrian MckemeyPresident - Certara Drug Development Solutions
- Ms. Rona AnhaltChief Human Resources Officer
- Mr. Daniel CorcoranSenior Vice President, General Counsel
- Mr. Eran BroshyIndependent Director$251,979
- Ms. Cynthia CollinsIndependent Director$241,979
- Ms. Rosemary CraneIndependent Director$239,479
- Ms. Nancy KilleferIndependent Director$251,979
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 37
- Environment
- 17
- Social
- 67
- Governance
- 27
- Direct emissions (scope 1)
- 363.34 t
- Energy emissions (scope 2)
- 816.41 t
- Value chain emissions (scope 3)
- 7,765.85 t
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Certara Inc has a strong reputation in the pharmaceutical industry due to its advanced technology and expertise in pharmacokinetic modeling and simulation.
- The company offers a comprehensive range of software solutions and consulting services, which enables it to provide tailored solutions to pharmaceutical companies.
- Certara Inc has a well-established customer base, including top pharmaceutical companies and regulatory agencies, which provides a stable source of revenue.
Weaknesses
- Certara Inc relies heavily on the pharmaceutical industry, which is subject to market fluctuations and regulatory changes. These factors can impact the company's financial performance.
- The company faces intense competition from other technology and consulting firms in the pharmaceutical industry, which could potentially affect its market share.
Opportunities
- As pharmaceutical companies continue to focus on drug development and regulatory approval, there is an increasing demand for Certara's services and software solutions.
- The incorporation of artificial intelligence and machine learning in pharmacokinetic modeling presents an opportunity for Certara Inc to further enhance its offerings and gain a competitive edge.
Threats
- Changes in government regulations and industry standards can pose a threat to Certara Inc's business operations and may require the company to adapt its services accordingly.
- The emergence of new competitors in the pharmaceutical technology and consulting space could potentially erode Certara Inc's market share and impact its revenue growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.